Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 19 (3) , 270-279.e3
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company
This publication has 20 references indexed in Scilit:
- Age is a prognostic factor affecting survival in lung cancer patientsOncology Letters, 2013
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialThe Lancet Oncology, 2010
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2Journal of Clinical Oncology, 2010
- Current Treatments for Advanced Stage Non-Small Cell Lung CancerProceedings of the American Thoracic Society, 2009
- Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancerThorax, 2004
- Vascular endothelial growth factor and its receptorsCytokine & Growth Factor Reviews, 1996
- Age and the treatment of lung cancer.Thorax, 1996
- Interpretation of Subgroup Analyses in Clinical TrialsDrug Information Journal, 1995
- Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)European Journal of Cancer, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958